In liver cirrhosis, portal hypertension is a consequence of enhanced intrahepatic vascular resistance and portal blood flow. Significant vasodilation in the arterial splanchnic district is crucial for an increase in portal flow. In this pathological condition, increased levels of circulating endogenous vasodilators, including nitric oxide, prostacyclin, carbon monoxide, epoxyeicosatrienoic acids, glucagon, endogenous cannabinoids, and adrenomedullin, and a decreased vascular response to vasoconstrictors are the main mechanisms underlying splanchnic vasodilation. In this review, the molecular pathways leading to splanchnic vasodilation will be discussed in detail.

Keywords:
Liver cirrhosis, Liver, Vascular tone, Vasoactive molecules, Splanchnic vasodilation
1.
de Franchis R; Baveno VI Faculty: Expanding consensus in portal hypertension - report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743-752.
2.
Møller S, Bendtsen F: Cirrhotic multiorgan syndrome. Dig Dis Sci 2015;60:3209-3225.
3.
Gatta A, Verardo A, Di Pascoli M, Giannini S, Bolognesi M: Hepatic osteodystrophy. Clin Cases Miner Bone Metab 2014;11:185-191.
4.
Mulvany MJ, Aalkiaer C: Structure and function of small arteries. Physiol Rev 1990;70:921-961.
5.
Rodríguez-Vilarrupla A, Fernández M, Bosch J, García-Pagán JC: Current concepts on the pathophysiology of portal hypertension. Ann Hepatol 2007;6:28-36.
6.
Bolognesi M, Verardo A, Di Pascoli M: Peculiar characteristics of portal-hepatic hemodynamics of alcoholic cirrhosis. World J Gastroenterol 2014;20:8005-8010.
7.
Gupta TK, Toruner M, Chung MK, Groszmann RJ: Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998;28:926-931.
8.
Battista S, Bar F, Mengozzi G, Zanon E, Grosso M, Molino G: Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol 1997;26:75-80.
9.
Hu LS, George J, Wang JH: Current concepts on the role of nitric oxide in portal hypertension. World J Gastroenterol 2013;19:1707-1717.
10.
Wiest R, Shah V, Sessa WC, Groszmann RJ: NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999;276:G1043-G1051.
11.
Morales-Ruiz M, Jiménez W, Pérez-Sala D, Ros J, Leivas A, Lamas S, Rivera F, Arroyo V: Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. Hepatology 1996;24:1481-1486.
12.
Martin P-Y, Xu DL, Niederberger M, et al: Upregulation of the endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am J Physiol 1996;270:F494-F499.
13.
Abraldes JG, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa WC, Groszmann RJ: Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol 2006;290:G980-G987.
14.
Theodorakis NG, Wang YN, Wu JM, Maluccio MA, Sitzmann JV, Skill NJ: Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model. Am J Physiol Gastrointest Liver Physiol 2009;297:G792-G799.
15.
Cahill PA, Redmond EM, Hodges R, Zhang S, Sitzmann JV: Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol 1996;25:370-378.
16.
Tsai MH, Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ: Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology 2003;125:1452-1461.
17.
Fernandez M: Molecular pathophysiology of portal hypertension. Hepatology 2015;61:1406-1415.
18.
Wiest R, Cadelina G, Milstien S, McCuskey RS, Garcia-Tsao G, Groszmann RJ: Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology 2003;38:1508-1515.
19.
Iwakiri Y, Tsai MH, McCabe TJ, Gratton JP, Fulton D, Groszmann RJ, et al: Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol Heart Circ Physiol 2002;282:H2084-H2090.
20.
Shah V, Wiest R, Garcia-Cardena G, Cadelina G, Groszmann RJ, Sessa WC: Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am J Physiol 1999;277:G463-G468.
21.
Grace JA, Klein S, Herath CB, Granzow M, Schierwagen R, Masing N, Walther T, Sauerbruch T, Burrell LM, Angus PW, Trebicka J: Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology 2013;145:e875.
22.
Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ: Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol Gastrointest Liver Physiol 2002;283:G1074-G1081.
23.
Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balanzo J, Vilardell F, Mourelle M, Moncada S: Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993;18:1139-1143.
24.
Ferguson JW, Dover AR, Chia S, Cruden NL, Hayes PC, Newby DE: Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites. Gut 2006;55:542-546.
25.
Kajita M, Murata T, Horiguchi K, Iizuka M, Hori M, Ozaki H: iNOS expression in vascular resident macrophages contributes to circulatory dysfunction of splanchnic vascular smooth muscle contractions in portal hypertensive rats. Am J Physiol Heart Circ Physiol 2011;300:H1021-H1031.
26.
Kwon SY, Groszmann RJ, Iwakiri Y: Increased neuronal nitric oxide synthase interaction with soluble guanylate cyclase contributes to the splanchnic arterial vasodilation in portal hypertensive rats. Hepatol Res 2007;37:58-67.
27.
Di Pascoli M, Zampieri F, Quarta S, Sacerdoti D, Merkel C, Gatta A, Bolognesi M: Heme oxygenase regulates renal arterial resistance and sodium excretion in cirrhotic rats. J Hepatol 2011;54:258-264.
28.
Zhang F, Kaide JI, Rodriguez-Mulero F, Abraham NG, Nasjletti A: Vasoregulatory function of heme-heme oxygenase-carbon monoxide system. Am J Hypertens 2001;14:62S-67S.
29.
De las Heras D, Fernández J, Ginès P, Cárdenas A, Ortega R, Navasa M, Barberá JA, Calahorra B, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J: Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology 2003;38:452-459.
30.
Fernandez M, Bonkovsky H: Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats. Hepatology 1999;29:1672-1679.
31.
Chen YC, Gines P, Yang J, et al: Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats. Hepatology 2004;39:1075-1087.
32.
Bolognesi M, Sacerdoti D, Di Pascoli M, Angeli P, Quarta S, Sticca A, Pontisso P, Merkel C, Gatta A: Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites. Gut 2005;54:1630-1636.
33.
Sacerdoti D, Abraham NG, Oyekan AO, Yang L, Gatta A, McGiff JC: Role of the heme oxygenases in abnormalities of the mesenteric circulation in cirrhotic rats. J Pharmacol Exp Ther 2004;308:636-643.
34.
Suematsu M, Ishimra Y: The heme oxygenase-carbon monoxide system: a regulator of hepatobiliary functions. Hepatology 2000;31:3-6.
35.
Moreau R: Heme oxygenase: protective enzyme or portal hypertensive molecule? J Hepatol 2001;34:936-939.
36.
Bolognesi M, Sacerdoti D, Piva A, Di Pascoli M, Zampieri F, Quarta S, Motterlini R, Angeli P, Merkel C, Gatta A: Carbon monoxide-mediated activation of large-conductance calcium-activated potassium channels contributes to mesenteric vasodilatation in cirrhotic rats. J Pharmacol Exp Ther 2007;321:187-194.
37.
Piva A, Zampieri F, Di Pascoli M, Gatta A, Sacerdoti D, Bolognesi M: Mesenteric arteries responsiveness to acute variations of wall shear stress is impaired in rats with liver cirrhosis. Scand J Gastroenterol 2012;47:1003-1013.
38.
Jeremy JY, Mikhailidis DP, Karatapanis S, Harry D, Burroughs AK, McIntyre N, Stansby G, Jacobs M, McCormick A: Altered prostacyclin synthesis by aortae from hepatic portal vein-constricted rats: evidence for effects on protein kinase C and calcium. J Hepatol 1994;21:1017-1022.
39.
Ohta M, Kishihara F, Hashizume M, Kawanaka H, Tomikawa M, Higashi H, Tanoue K, Sugimachi K: Increased prostacyclin content in gastric mucosa of cirrhotic patients with portal hypertensive gastropathy. Prostaglandins Leukot Essent Fatty Acids 1995;53:41-45.
40.
Bruix J, Bosch J, Kravetz D, Mastai R, Rodés J: Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985;88:430-435.
41.
Oberti F, Sogni P, Cailmail S, Moreau R, Pipy B, Lebrec D: Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic and intrahepatic portal hypertension. Hepatology 1993;18:621-627.
42.
Hou MC, Cahill PA, Zhang S, et al: Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: role in the hyperdynamic circulation. Hepatology 1998;27:20-27.
43.
Tsugawa K, Hashizume M, Migou S, Kishihara F, Kawanaka H, Tomikawa M, Sugimachi K: A selective cyclo-oxygenase-2 inhibitor, NS-398, may improve portal hypertension without inducing gastric mucosal injury. J Gastroenterol Hepatol 1999;14:642-651.
44.
Fernández M, García-Pagán JC, Casadevall M, Mourelle MI, Piqué JM, Bosch J, Rodés J: Acute and chronic cyclooxygenase blockage in portal-hypertensive rats: influence in nitric oxide biosynthesis. Gastroenterology 1996;110:1529-1535.
45.
Rautou PE, Bresson J, Sainte-Marie Y, Vion AC, Paradis V, Renard JM, Devue C, Heymes C, Letteron P, Elkrief L, Lebrec D, Valla D, Tedgui A, Moreau R, Boulanger CM: Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis. Gastroenterology 2012;143:166-176.e6.
46.
Sacerdoti D, Pesce P, Di Pascoli M, Brocco S, Cecchetto L, Bolognesi M: Arachidonic acid metabolites and endothelial dysfunction of portal hypertension. Prostaglandins Other Lipid Mediat 2015;120:80-90.
47.
Di Pascoli M, Zampieri F, Verardo A, Pesce P, Turato C, Angeli P, Sacerdoti D, Bolognesi M: Inhibition of epoxyeicosatrienoic acid production in rats with cirrhosis has beneficial effects on portal hypertension by reducing splanchnic vasodilation. Hepatology 2016;64:923-930.
48.
Sacerdoti D, Mania D, Jiang H, Pesce P, Gaiani S, Gatta A, Bolognesi M: Increased EETs participate in peripheral endothelial dysfunction of cirrhosis. Prostaglandins Other Lipid Mediat 2012;98:129-132.
49.
Di Pascoli M, Turato C, Zampieri F, Verardo A, Pontisso P, Pesce P, Sacerdoti D, Bolognesi M: Changes in gene expression of cytochrome P-450 in liver, kidney and aorta of cirrhotic rats. Prostaglandins Other Lipid Mediat 2015;120:134-138.
50.
Archer SL, Gragasin FS, Wu X, Wang S, McMurtry S, Kim DH, Platonov M, Koshal A, Hashimoto K, Campbell WB, Falck JR, Michelakis ED: Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation 2003;107:769-776.
51.
Campbell WB, Gebremedhin D, Pratt PF, Harder DR: Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996;78:415-423.
52.
Sacerdoti D, Pesce P, Di Pascoli M, Bolognesi M: EETs and HO-1 cross-talk. Prostaglandins Other Lipid Mediat 2016;125:65-79.
53.
Sacerdoti D, Bolognesi M, Di Pascoli M, Gatta A, McGiff JC, Schwartzman ML, Abraham NG: Rat mesenteric arterial dilator response to 11,12-epoxyeicosatrienoic acid is mediated by activating heme oxygenase. Am J Physiol Heart Circ Physiol 2006;291:H1999-H2002.
54.
Bolognesi M, Zampieri F, Di Pascoli M, Verardo A, Turato C, Calabrese F, Lunardi F, Pontisso P, Angeli P, Merkel C, Gatta A, Sacerdoti D: Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats. Liver Int 2011;31:881-890.
55.
Gomis R, Fernández-Alvarez J, Pizcueta P, Fernández M, Casamitjana R, Bosch J, Rodés J: Impaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial portal vein ligation. Hepatology 1994;19:1257-1261.
56.
Silva G, Navasa M, Bosch J, Chesta J, Pilar Pizcueta M, Casamitjana R, Rivera F, Rodés J: Hemodynamic effects of glucagon in portal hypertension. Hepatology 1990;11:668-673.
57.
Kravetz D, Bosch J, Arderiu MT, Pizcueta MP, Casamitjana R, Rivera F, Rodés J: Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol 1988;254:G322-G328.
58.
Wahren J, Eriksson LS: The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis. Scand J Gastroenterol Suppl 1986;119:103-108.
59.
Ralevic V, Kendall DA, Randall MD, Smart D: Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function. Life Sci 2002;71:2577-2594.
60.
Caraceni P, Viola A, Piscitelli F, Giannone F, Berzigotti A, Cescon M, Domenicali M, Petrosino S, Giampalma E, Riili A, Grazi G, Golfieri R, Zoli M, Bernardi M, Di Marzo V: Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int 2010;30:816-825.
61.
Bátkai S, Járai Z, Wagner JA, Goparaju SK, Varga K, Liu J, Wang L, Mirshahi F, Khanolkar AD, Makriyannis A, Urbaschek R, Garcia N, Sanyal AJ, Kunos G: Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001;7:827-832.
62.
Ros J, Clària J, To-Figueras J, Planagumà A, Cejudo-Martín P, Fernández-Varo G, Martín-Ruiz R, Arroyo V, Rivera F, Rodés J, Jiménez W: Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002;122:85-93.
63.
Bátkai S, Mukhopadhyay P, Harvey-White J, Kechrid R, Pacher P, Kunos G: Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol 2007;293:H1689-H1695.
64.
Domenicali M, Caraceni P, Giannone F, Pertosa AM, Principe A, Zambruni A, Trevisani F, Croci T, Bernardi M: Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis. Gastroenterology 2009;137:341-349.
65.
Baldassarre M, Giannone FA, Napoli L, Tovoli A, Ricci CS, Tufoni M, Caraceni P: The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives. Liver Int 2013;33:1298-1308.
66.
Domenicali M, Ros J, Fernández-Varo G, Cejudo-Martín P, Crespo M, Morales-Ruiz M, Briones AM, Campistol JM, Arroyo V, Vila E, Rodés J, Jiménez W: Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Gut 2005;54:522-527.
67.
Kojima H, Sakurai S, Uemura M, Satoh H, Nakashima T, Minamino N, Kangawa K, Matsuo H, Fukui H: Adrenomedullin contributes to vascular hyporeactivity in cirrhotic rats with ascites via a release of nitric oxide. Scand J Gastroenterol 2004;39:686-693.
68.
Tahan V, Avsar E, Karaca C, Uslu E, Eren F, Aydin S, Uzun H, Hamzaoglu HO, Besisik F, Kalayci C, Okten A, Tozun N: Adrenomedullin in cirrhotic and non-cirrhotic portal hypertension. World J Gastroenterol 2003;9:2325-2327.
69.
Guevara M, Ginès P, Jiménez W, Sort P, Fernández-Esparrach G, Escorsell A, Bataller R, Bosch J, Arroyo V, Rivera F, Rodés J: Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 1998;114:336-343.
70.
Kojima H, Tsujimoto T, Uemura M, Takaya A, Okamoto S, Ueda S, Nishio K, Miyamoto S, Kubo A, Minamino N, Kangawa K, Matsuo H, Fukui H: Significance of increased plasma adrenomedullin concentration in patients with cirrhosis. J Hepatol 1998;28:840-846.
71.
Sugo S, Minamino N, Shoji H, Kangawa K, Kitamura K, Eto T, Matsuo H: Interleukin-1, tumor necrosis factor and lipopolysaccharide additively stimulate production of adrenomedullin in vascular smooth muscle cells. Biochem Biophys Res Commun 1995;207:25-32.
72.
Genesca J, Gonzalez A, Catalan R, Segura R, Martinez M, Esteban R, Groszmann RJ, Guardia J: Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis: relationship to nitric oxide. Dig Dis Sci 1999;44:372-376.
73.
Nishimatsu H, Suzuki E, Nagata D, Moriyama N, Satonaka H, Walsh K, Sata M, Kangawa K, Matsuo H, Goto A, Kitamura T, Hirata Y: Adrenomedullin induces endothelium-dependent vasorelaxation via the phosphatidylinositol 3-kinase/Akt-dependent pathway in rat aorta. Circ Res 2001;89:63-70.
74.
Dietrich P, Moleda L, Kees F, Müller M, Straub RH, Hellerbrand C, Wiest R: Dysbalance in sympathetic neurotransmitter release and action in cirrhotic rats: impact of exogenous neuropeptide Y. J Hepatol 2013;58:254-261.
75.
Pernow J, Lundberg JM: Modulation of noradrenaline and neuropeptide Y (NPY) release in the pig kidney in vivo: involvement of alpha-2, NPY and angiotensin II receptors. Naunyn Schmiedebergs Arch Pharmacol 1989;340:379-385.
76.
Lakatos PL, Firneisz G, R ak oczy G, Selmeci L, Szalay F: Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in patients with primary biliary cirrhosis. J Hepatol 1999;30:740.
77.
Moleda L, Trebicka J, Dietrich P, Gäbele E, Hellerbrand C, Straub RH, Sauerbruch T, Schoelmerich J, Wiest R: Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction. Gut 2011;60:1122-1132.
78.
Meng J, Wang Q, Liu K, Yang S, Fan X, Liu B, He C, Wu X: Systemic and splanchnic lipopolysaccharide and endothelin-1 plasma levels in liver cirrhosis before and after transjugular intrahepatic portosystemic shunt. Gastroenterol Res Pract 2016;2016:8341030.
79.
Du QH, Han L, Jiang JJ, Li PT, Wang XY, Jia X: Increased endothelin receptor B and G protein coupled kinase-2 in the mesentery of portal hypertensive rats. World J Gastroenterol 2013;19:2065-2072.
80.
Hennenberg M, Trebicka J, Kohistani AZ, Heller J, Sauerbruch T: Vascular hyporesponsiveness to angiotensin II in rats with CCl(4)-induced liver cirrhosis. Eur J Clin Invest 2009;39:906-913.
81.
Hennenberg M, Trebicka J, Sauerbruch T, Heller J: Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 2008;57:1300-1314.
82.
Song D, Sharkey KA, Breitman DR, Zhang Y, Lee SS: Disordered central cardiovascular regulation in portal hypertensive and cirrhotic rats. Am J Physiol Gastrointest Liver Physiol 2001;280:G420-G430.
83.
Lee SS, Sharkey KA: Capsaicin treatment blocks development of hyperkinetic circulation in portal hypertensive and cirrhotic rats. Am J Physiol 1993;264:G868-G873.
84.
Liu H, Schuelert N, McDougall JJ, Lee SS: Central neural activation of hyperdynamic circulation in portal hypertensive rats depends on vagal afferent nerves. Gut 2008;57:966-973.
85.
Ezkurdia N, Raurell I, Rodríguez S, González A, Esteban R, Genescà J, Martell M: Inhibition of neuronal apoptosis and axonal regression ameliorates sympathetic atrophy and hemodynamic alterations in portal hypertensive rats. PLoS One 2014;9:e84374.
86.
Tsujimoto G, Honda K, Hoffman BB, Hashimoto K: Desensitization of postjunctional alpha 1- and alpha 2-adrenergic receptor-mediated vasopressor responses in rat harboring pheochromocytoma. Circ Res 1987;61:86-98.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.